-
Topical Pain Relief Market to Reach US$17.3 Bn by 2033, Growing at 5.2% CAGR: Persistence Market Research
03 Feb 2026 07:03 GMT
… relief products. Furthermore, the region benefits from an established retail network … , Advacare Pharma, Teva Pharmaceutical Industries, Bayer Healthcare, and GlaxoSmithKline leading the charge …
-
Celecoxib Benefit Seen in ctDNA-Positive Colon Cancer
04 Dec 2025 16:14 GMT
… , celecoxib showed no significant survival benefit (disease-free survival: AHR, 0 … a subset of patients who benefit most from adjuvant COX-inhibition … from multiple pharmaceutical companies including Bayer HealthCare, Boehringer Ingelheim, and Bristol Myers …
-
ASCO 2025: XOFIGO® (radium-223 dichloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
28 May 2025 12:29 GMT
… with valuable insights into the benefits of combining XOFIGO with … known radiographic progression free survival benefit. We are encouraged by … Injection [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, December 2019.
Choudhury A …
-
Real-World Analysis of Multidisciplinary Roles in the Management of Hepatocellular Carcinoma: The Mayo Clinic Experience
21 Jan 2026 22:55 GMT
… the drug names: “Sorafenib” (Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA), … CA, USA), and “Regorafenib” (Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA … advanced disease suggests potential benefit from coordinated hepatology–medical …
-
The Search for a Safer Anticoagulant
20 Jan 2026 12:10 GMT
… group of people who could benefit.”
Regarding any additional clinical indications … OCEANIC trials were funded by Bayer HealthCare. The LIBREXIA studies were funded … an advisor or consultant for Bayer HealthCare, Bristol-Myers Squibb, Janssen Pharmaceuticals …
-
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study.
13 Jan 2025 11:03 GMT
Alkaline phosphatase (ALP) declines and pain responses can occur during radium-223 (223Ra) treatment, but their association with treatment outcomes is unclear.
For patients with metastatic castration-resistant prostate cancer treated with 223Ra in the …
-
Contrast Media/Contrast Agent Market to Undertake Incredible Growth 2022- 2028 | Bayer HealthCare, Bracco Imaging S.p.A
28 Oct 2022 09:26 GMT
… :
Lantheus Medical Imaging, GE Healthcare, Bayer HealthCare, Bracco Imaging S.p.A … and competitive landscape structure.
☑ It benefits in creating an awareness of …
-
$32.2 Billion Worldwide Self-Care Medical Devices Industry to 2027 - Featuring Medtronic, Abbott Laboratories, Bayer Healthcare and ResMed Among Others - ResearchAndMarkets.com
27 Sep 2022 14:17 GMT
… & Johnson
Medtronic
Abbott Laboratories
Bayer HealthCare
Koninklijke Philips
General Electric Company … -care medical devices and the benefits of keeping a regular check …
-
Tivozanib Shows Benefits in Long-Term Survival for Relapsed/Refractory Renal Cell Carcinoma
10 May 2024 17:28 GMT
… improvements compared with sorafenib (Nexavar; Bayer Healthcare) in this patient population.1 … experience a long-term survival benefit from tivozanib over sorafenib.”1 …
-
Diabetes Monitoring Devices Market will generate new growth opportunities 2022-2028 | Bayer Healthcare AG, Medtronic
22 Feb 2022 11:13 GMT
… as this report will surely benefit their marketing strategies. The market … Vendors of this Market are: Bayer Healthcare AG, Medtronic, Dexcom, Sanofi S …
About
© 1995-2026